CRA consultant Becky Davis was interviewed by Managed Healthcare Executive at Asembia AXS25 Conference.
Davis discussed how the GLP-1 drug market is poised for major shifts over the next two years, driven by the introduction of new injectable and oral treatments, pricing pressures, and expanded indications. She notes that competition and price negotiations will likely drive down costs, while payers weigh coverage decisions amid growing demand.
Davis discussed the uneven employer-based insurance coverage for GLP-1 drugs, noting that access often depends on whether employers opt –in to cover these treatments. Davis emphasized that as GLP-1 indications expand, the value of treating obesity alongside other conditions may shift how employers and payers approach coverage decisions.
